Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Am J Hematol. 2015 Jan 30;90(4):334–338. doi: 10.1002/ajh.23939

Figure 2.

Figure 2

(A) Overall Survival of CLL/HL patients based on prior receipt of CLL therapy. (B) Overall survival of CLL/HL patients who had received previous purine analog therapy (PA) for CLL compared to those who did not receive PA therapy. (C) Overall survival of CLL/HL patients according to the International Prognostic Score (IPS).